Loading...

GenSight Biologics

ENXTPA:SIGHT
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SIGHT
ENXTPA
€43M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • GenSight Biologics has significant price volatility in the past 3 months.
SIGHT Share Price and Events
7 Day Returns
-13.1%
ENXTPA:SIGHT
0.4%
FR Biotechs
0.6%
FR Market
1 Year Returns
-50.9%
ENXTPA:SIGHT
-34.4%
FR Biotechs
-3.9%
FR Market
SIGHT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GenSight Biologics (SIGHT) -13.1% -24.4% -24.6% -50.9% - -
FR Biotechs 0.4% -3.2% 1.1% -34.4% -52% -36.4%
FR Market 0.6% -3.3% 3.8% -3.9% 27.3% 27.2%
1 Year Return vs Industry and Market
  • SIGHT underperformed the Biotechs industry which returned -34.4% over the past year.
  • SIGHT underperformed the Market in France which returned -3.9% over the past year.
Price Volatility
SIGHT
Industry
5yr Volatility vs Market
Related Companies

SIGHT Value

 Is GenSight Biologics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for GenSight Biologics. This is due to cash flow or dividend data being unavailable. The share price is €1.516.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GenSight Biologics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GenSight Biologics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:SIGHT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.37
ENXTPA:SIGHT Share Price ** ENXTPA (2019-05-22) in EUR €1.52
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.5x
France Market PE Ratio Median Figure of 419 Publicly-Listed Companies 17.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GenSight Biologics.

ENXTPA:SIGHT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:SIGHT Share Price ÷ EPS (both in EUR)

= 1.52 ÷ -1.37

-1.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GenSight Biologics is loss making, we can't compare its value to the FR Biotechs industry average.
  • GenSight Biologics is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does GenSight Biologics's expected growth come at a high price?
Raw Data
ENXTPA:SIGHT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
22.8%per year
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 0.34x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GenSight Biologics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GenSight Biologics's assets?
Raw Data
ENXTPA:SIGHT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.97
ENXTPA:SIGHT Share Price * ENXTPA (2019-05-22) in EUR €1.52
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.27x
France Market PB Ratio Median Figure of 620 Publicly-Listed Companies 1.44x
ENXTPA:SIGHT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:SIGHT Share Price ÷ Book Value per Share (both in EUR)

= 1.52 ÷ 0.97

1.57x

* Primary Listing of GenSight Biologics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GenSight Biologics is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess GenSight Biologics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GenSight Biologics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SIGHT Future Performance

 How is GenSight Biologics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GenSight Biologics expected to grow at an attractive rate?
  • Unable to compare GenSight Biologics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare GenSight Biologics's earnings growth to the France market average as it is expected to be loss making during the next 1-3 years.
  • GenSight Biologics's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:SIGHT Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:SIGHT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 22.8%
ENXTPA:SIGHT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 82.8%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.9%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 39.7%
France Market Earnings Growth Rate Market Cap Weighted Average 13.3%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:SIGHT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:SIGHT Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 24 -19 -22 1
2019-12-31 7 -23 -23 1
ENXTPA:SIGHT Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -28 -33
2018-09-30 4 -25 -30
2018-06-30 4 -21 -26
2018-03-31 4 -20 -25
2017-12-31 4 -19 -24
2017-09-30 3 -19 -23
2017-06-30 3 -20 -23
2017-03-31 3 -20 -22
2016-12-31 3 -20 -22
2016-09-30 3 -18 -20
2016-06-30 4 -17 -18
2016-03-31 4 -15 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • GenSight Biologics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • GenSight Biologics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:SIGHT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from GenSight Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:SIGHT Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.76 -0.70 -0.80 3.00
2019-12-31 -0.80 -0.80 -0.80 1.00
ENXTPA:SIGHT Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.37
2018-09-30 -1.21
2018-06-30 -1.06
2018-03-31 -1.08
2017-12-31 -1.10
2017-09-30 -1.14
2017-06-30 -1.18
2017-03-31 -1.26
2016-12-31 -1.36
2016-09-30 -1.36
2016-06-30 -1.35
2016-03-31 -1.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GenSight Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GenSight Biologics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GenSight Biologics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SIGHT Past Performance

  How has GenSight Biologics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GenSight Biologics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GenSight Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GenSight Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GenSight Biologics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GenSight Biologics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GenSight Biologics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:SIGHT Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 4.35 -33.45 8.36 29.03
2018-09-30 4.04 -29.56 8.39 24.78
2018-06-30 3.74 -25.66 8.94 20.01
2018-03-31 3.72 -24.88 9.23 19.09
2017-12-31 3.70 -24.11 9.02 18.68
2017-09-30 3.41 -23.50 8.95 17.84
2017-06-30 3.12 -22.88 8.89 17.01
2017-03-31 3.06 -22.48 8.00 17.46
2016-12-31 3.00 -22.08 7.11 17.91
2016-09-30 3.32 -20.21 6.27 15.83
2016-06-30 3.64 -18.34 5.34 13.74
2016-03-31 3.60 -15.99 4.78 11.92
2015-12-31 3.56 -13.65 4.23 10.09
2015-09-30 2.88 -11.26 3.33 9.33
2015-06-30 2.21 -8.88 2.54 8.56
2015-03-31 1.65 -7.77 2.15 7.33
2014-12-31 1.10 -6.67 1.76 6.09
2013-12-31 0.91 -2.76 1.05 2.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GenSight Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GenSight Biologics has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GenSight Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GenSight Biologics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GenSight Biologics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SIGHT Health

 How is GenSight Biologics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GenSight Biologics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GenSight Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GenSight Biologics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GenSight Biologics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GenSight Biologics Company Filings, last reported 4 months ago.

ENXTPA:SIGHT Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 23.87 3.44 26.24
2018-09-30 23.87 3.44 26.24
2018-06-30 44.64 3.41 41.68
2018-03-31 44.64 3.41 41.68
2017-12-31 55.00 3.03 55.45
2017-09-30 55.00 3.03 55.45
2017-06-30 66.27 2.70 63.62
2017-03-31 66.27 2.70 63.62
2016-12-31 53.34 2.92 53.98
2016-09-30 53.34 2.92 53.98
2016-06-30
2016-03-31 29.33 0.62 30.06
2015-12-31 29.33 0.62 30.06
2015-09-30 29.33 0.62 30.06
2015-06-30 6.04 0.64 6.00
2015-03-31 6.04 0.64 6.00
2014-12-31 10.58 0.63 12.07
2013-12-31 16.97 0.00 17.09
  • GenSight Biologics's level of debt (14.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 14.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GenSight Biologics has less than a year of cash runway based on current free cash flow.
  • GenSight Biologics has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.1% each year.
X
Financial health checks
We assess GenSight Biologics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GenSight Biologics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SIGHT Dividends

 What is GenSight Biologics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GenSight Biologics dividends. Estimated to be 0% next year.
If you bought €2,000 of GenSight Biologics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GenSight Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GenSight Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:SIGHT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 0.9%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:SIGHT Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GenSight Biologics has not reported any payouts.
  • Unable to verify if GenSight Biologics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GenSight Biologics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GenSight Biologics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of GenSight Biologics's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess GenSight Biologics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GenSight Biologics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GenSight Biologics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SIGHT Management

 What is the CEO of GenSight Biologics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bernard Gilly
COMPENSATION €1,558,018
AGE 61
TENURE AS CEO 7.3 years
CEO Bio

Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceuticals, SA in 2005 and serves as its Chairman, Chief Executive Officer and President. Dr. Gilly Co-Founded GenSight Biologics SA in 2011 and serves as its Chief Executive Officer and served as its Executive Chairman. Dr. Gilly has been the President and General Manager of Fovea since November 2005. He serves as the Chief Executive Officer of GenSight Biologics SA. He has been the Executive Chairman of Pixium Vision SA since January 6, 2015 and was its Interim Chief Executive Officer since April 24, 2019 until May 13, 2019. He Co-Founded Gecko Biomedical SAS and serves as its Executive Chairman. In 2012, he founded the iBionext Network. He is a Director at GrAI Matter Labs. He served as Senior Vice President of the Ophthalmology Division of Sanofi until March 2012. He served as the President of TRANSGENE. He was a Venture Partner of Sofinnova Partners from December 2000 to October 2005 and joined in December 2000. He was a Partner at Sofinnova Partners from 2000 to 2005. He began his career as a Scientist at the Institut National de la Recherche Agronomique (INRA). He served as a Consultant of Food and Agriculture Organization of the United Nations and International Monetary Fund (IMF). He served as a Co-President and Vice President of Research and Development of Sanofi Pasteur SA and Vice President of Research and Development of bioMérieux SA. Dr. Gilly served as the Chief Executive Officer of TRANSGENE (Director General) from 1992 to January 2001. From 1994 to June 1997, he served as Research Director of BioMerieux. He served in various capacities at Pasteur Merieux, including Vice President of Research and Development from 1990 to 1994. He serves as the Chairman of the Board of Sofinnova Partners. He serves as Chairman of the Supervisory Board of Faust Pharmaceuticals SA. He serves as Director at GenSight Biologics SA. He serves as Member of the Board of Directors of Chronocam SAS, Brain Ever, Chrono Life, Tilak, Noxxon Pharma and ENS Lyon. He served as a Member of the Board of Directors of HighDeal S.A., CNRS, Ecole Normale Supérieure de Lyon and Institut National de la Santé et de la Recherche Médicale (INSERM). He served as the Chairman of the Board of WebSurg. He served as the Chairman of Eye Tech Care SA. He served as a Director of Sequoia Pharmaceuticals, Inc. He served as the Chairman at Enterome SA. until September 2015 and also served as its Non-Executive Director. He was a Director of Kala Pharmaceuticals, Inc. since November 27, 2012. He served as the Chairman of the Board of CareX S.A. and Domain Therapeutics S.A. He served as a Director of Domain Therapeutics S.A. He served as an Independent Director of Wavecom SA from April 1999 to March 6, 2009. Dr. Gilly is a graduate of Ecole Nationale d'Agronomie and has a Ph.D. in Biology and Bio-Economics from Université de Rennes I and University of Rhode-Island. He also has an MBA from INSEAD (France). He holds an AMP from INSEAD.

CEO Compensation
  • Bernard's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Bernard's remuneration is higher than average for companies of similar size in France.
Management Team Tenure

Average tenure of the GenSight Biologics management team in years:

2.7
Average Tenure
  • The tenure for the GenSight Biologics management team is about average.
Management Team

Bernard Gilly

TITLE
Co-Founder
COMPENSATION
€2M
AGE
61
TENURE
7.3 yrs

José-Alain Sahel

TITLE
Scientific Founder

Botond Roska

TITLE
Scientific Founder & Chairman of Scientific Advisory Board

Jean Bennett

TITLE
Scientific Founder & Vice Chairman of Scientific Advisory Board

Luk Vandenberghe

TITLE
Scientific Founder & Member of Scientific Advisory Board

Serge Picaud

TITLE
Scientific Founder & Member of Scientific Advisory Board

Connie Cepko

TITLE
Scientific Founders & Member of Scientific Advisory Board

Thomas Gidoin

TITLE
Chief Financial Officer
AGE
35
TENURE
3.8 yrs

Julio Benedicto

TITLE
Vice President of Marketing
TENURE
1.3 yrs

Barrett Katz

TITLE
Chief Medical Officer
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the GenSight Biologics board of directors in years:

7.1
Average Tenure
63
Average Age
  • The tenure for the GenSight Biologics board of directors is about average.
Board of Directors

Mike Wyzga

TITLE
Chairman of the Board
COMPENSATION
€170K
AGE
63
TENURE
3.2 yrs

Bernard Gilly

TITLE
Co-Founder
COMPENSATION
€2M
AGE
61

José-Alain Sahel

TITLE
Scientific Founder

Botond Roska

TITLE
Scientific Founder & Chairman of Scientific Advisory Board

Jean Bennett

TITLE
Scientific Founder & Vice Chairman of Scientific Advisory Board

Luk Vandenberghe

TITLE
Scientific Founder & Member of Scientific Advisory Board
TENURE
7.1 yrs

Serge Picaud

TITLE
Scientific Founder & Member of Scientific Advisory Board
TENURE
7.1 yrs

Connie Cepko

TITLE
Scientific Founders & Member of Scientific Advisory Board
TENURE
7.1 yrs

Peter Goodfellow

TITLE
Independent Director
COMPENSATION
€76K
AGE
67

Ernst Bamberg

TITLE
Member of Scientific Advisory Board
TENURE
7.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess GenSight Biologics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GenSight Biologics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SIGHT News

Simply Wall St News

Investors Who Bought GenSight Biologics (EPA:SIGHT) Shares A Year Ago Are Now Down 64%

Given that GenSight Biologics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last year GenSight Biologics saw its revenue grow by 20%.

Simply Wall St -

Do Institutions Own GenSight Biologics S.A. (EPA:SIGHT) Shares?

A look at the shareholders of GenSight Biologics S.A. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … With a market capitalization of €82m, GenSight Biologics is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

GenSight Biologics SA (EPA:SIGHT): When Will It Breakeven?

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. … The €71.97m market-cap company announced a latest loss of -€24.11m on 31 December 2017 for its most recent financial year result. … In this article, I will touch on the expectations for SIGHT’s growth and when analysts expect the company to become profitable

Simply Wall St -

Why You Should Be Bearish On GenSight Biologics SA. (EPA:SIGHT)

It's crucial to understand if a company has a strong future based on its current operations and financial status. … SIGHT has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like SIGHT as a business is its low level of fixed assets on its balance sheet (1.21% of total assets).

Simply Wall St -

GenSight Biologics SA. (EPA:SIGHT): Is Breakeven Near?

I’ve put together a brief outline of industry analyst expectations for SIGHT, its year of breakeven and its implied growth rate. … Check out our latest analysis for GenSight Biologics SIGHT is bordering on breakeven, according to analysts. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Simply Wall St -

SIGHT Company Info

Description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye, and central nervous system. The company develops its products through gene therapy-based approach with technology platforms of mitochondrial targeting sequence and optogenetics. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy associated with mutation in the ND4 gene; and GS030 that comprises a gene encoding photoactivatable channelrhodopsin for the treatment of reinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company also develops products that are preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.

Details
Name: GenSight Biologics S.A.
SIGHT
Exchange: ENXTPA
Founded: 2012
€43,428,156
28,646,541
Website: http://www.gensight-biologics.com
Address: GenSight Biologics S.A.
74, rue du Faubourg Saint-Antoine,
Paris,
Ile-de-France, 75012,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA SIGHT Ordinary Shares Euronext Paris FR EUR 13. Jul 2016
OTCPK GSGT.F Ordinary Shares Pink Sheets LLC US USD 13. Jul 2016
DB G49N Ordinary Shares Deutsche Boerse AG DE EUR 13. Jul 2016
LSE 0RIM Ordinary Shares London Stock Exchange GB EUR 13. Jul 2016
Number of employees
Current staff
Staff numbers
32
GenSight Biologics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 00:51
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/04/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.